Short Courses

Sunday, April 7

Morning, 10:00 am - 1:00 pm

SC1: Preclinical and Clinical Assessment of Immunogenicity: Focus on New Modalities Including Bi- and Tri-Specific Antibodies, Oligonucleotides, Gene Therapy and CAR T - Detailed Agenda (Federal Complex)

Darshana Jani, MSc, Associate Director, Global Lead Biologics, Clinical Assay Group, Global Product Development, Pfizer, Inc.

Magdalena Tary-Lehmann, MD, PhD, CSO, Cellular Technology Limited (CTL); Adjunct Associate Professor of Pathology, Case Western Reserve University (CWRU) 


Rama Boyanapalli, PhD, Director, Bioanalytical and Biomarker Development, Wave Life Sciences

Linzhi Chen, PhD, Senior Research Fellow & Bioanalytical Group Leader, Boehringer Ingelheim Pharmaceuticals

Kosalaram Goteti, PhD, Director, Site Head of Pharmacometry, EMD Serono

SC2: Translational Biotherapeutic Development Strategies Part 1: Discovery, Molecular Assessment and Early Stage Development - Detailed Agenda (Back Bay Complex)

Juan Carlos Almagro, PhD, Founder and Director, GlobalBio, Inc.

Zhiqiang An, PhD, Professor, Chemistry; Director, Texas Therapeutics Institute, University of Texas Health Science Center at Houston

Gadi Bornstein, PhD, Senior Director, Biologics Discovery, TESARO, Inc.

SC3: Selection, Screening and Engineering for Affinity Reagents - Detailed Agenda (Washington)

Jonas V. Schaefer, PhD, Lab Head/Investigator II, Novartis Institutes for BioMedical Research (NIBR)

Jürgen Klattig, PhD, Associate Director, Discovery Alliances and Technologies, Morphosys AG

SC4: Understanding and Modulating Tumor Microenvironment for Immunotherapy - Detailed Agenda (Tremont)

David A. Eavarone, PhD, Associate Principal Scientist, Harbour Biomed

Afternoon, 2:30 - 5:30 pm

SC5: In silico Immunogenicity Predictions (Hands-On) Workshop- Detailed Agenda (Federal Complex)

Vinodh B. Kurella, PhD, Principal Scientist, Protein Engineering, Merrimack Pharmaceuticals

Daron Forman, PhD, Principal Scientist, Molecular Discovery Technologies, Bristol-Myers Squibb

SC7: Translational Biotherapeutic Development Strategies Part 2: Analytical and Clinical Considerations - Detailed Agenda  (Back Bay Complex)

Zhiqiang An, PhD, Professor, Chemistry; Director, Texas Therapeutics Institute, University of Texas Health Science Center at Houston

Scott L. Klakamp, PhD, Senior Director & Head, Biophysics, Biologics Development Sciences, Janssen BioTherapeutics

Liming Liu, PhD, Senior Principal Scientist, Pharmacokinetics, Pharmacodynamics and Drug Metabolism (PPDM), Merck Research Laboratories

An Song, PhD, Senior Vice President, Development Sciences, Immune-Onc Therapeutics, Inc.

Tuesday, April 9

DINNER, 6:00 - 8:30 pm

SC9: Introduction to Biophysical Analysis for Biotherapeutics: Development Applications - Detailed Agenda (Washington)

Christine P. Chan, PhD, Principal Scientist, Global Manufacturing Science & Technology, Sanofi

SC10: CAR T-Cell Therapy for Solid Tumors - Detailed Agenda (Back Bay Complex)

Soldano Ferrone, MD, PhD, Division of Surgical Oncology, Surgery, Massachusetts General Hospital, Harvard Medical School


Moonsoo M. Jin, PhD, Professor, Biomedical Engineering, Radiology & Surgery, Molecular Imaging Innovations Institute, Weill Cornell Medical College

Tara Arvedson, PhD, Director, Oncology Research, Amgen

SC11: Developability of Bispecific Antibodies: Formats and Applications - Detailed Agenda (Federal Complex)

Nimish Gera, PhD, Director, Research and Development, Mythic Therapeutics

Thursday, April 11

dinner, 5:45 - 8:15 pm

SC12: Design Strategies and Development of ADCs - Detailed Agenda (Back Bay Complex)

Robert Lutz, PhD, Principal Consultant, Crescendo Biopharma Consulting

SC13: Bioassay Quality by Design- Detailed Agenda (Federal Complex)

Thomas Little, PhD, President and CEO, Bioassay Sciences, Thomas A. Little Consulting

DINNER, 5:45 - 8:45 pm

SC15: Transient Protein Production in Mammalian Cells - Detailed Agenda (Washington)

Richard Altman, MS, Staff Scientist, Life Science Solutions, Thermo Fisher Scientific

Henry C. Chiou, PhD, Director, Cell Biology, Life Science Solutions, Thermo Fisher Scientific

Bojiao Yin, PhD, Scientist, Protein Technologies, Amgen

* Separate Registration Required.

Japan-Flag Korea-Flag China-Traditional-Flag China-Simplified-Flag

Speaker Proposal

Premier Sponsors

View By: